Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Transpl Infect Dis. 2018 Aug 30;20(6):e12974. doi: 10.1111/tid.12974

TABLE 1.

Baseline characteristics of kidney transplant recipients

GN
(n=803)		 HTN
(n=442)		 DM
(n=947)		 PKD
(n=549)
Age (years), mean 45.3 ± 13.2 53.2 ± 12.4* 54.8 ± 10.1* 52.7 ± 9.1*
Female, n (%)  340 (42%)  125 (28%)*  322 (34%)* 256 (47%)
White ethnicity, n (%)  646 (80%)  275 (62%)*  788 (83%) 510 (93%)*
Pre-transplant dialysis, n (%) 592 (74%) 378 (86%)* 804 (85%)* 324 (59%)*
Dialysis duration prior to transplant
(months), mean		 19.6 ± 22.9 26.0 ± 25.1* 20.7 ± 20.0* 14.0 ± 24.8*
Panel reactive antibody >10%, n (%) 71 (19%) 37 (17%) 82 (17%) 50 (19%)
Deceased donor, n (%) 422 (53%) 327 (74%)* 623 (66%)* 301 (55%)
Donor age (years), mean 41.8 ± 14.3 43.7 ± 15.1* 43.9 ± 14.8* 43.6 ± 14.3*
HLA mismatch >2, n (%) 568 (71%) 352 (80%)* 675 (71%) 427 (78%)*
Delayed graft function, n (%) 111 (14%) 115 (26%)* 227 (24%)* 74 (13%)
Induction, n (%)
 • Alemtuzumab
 • Basiliximab
 • Thymoglobulin
 • None		  
114 (14%)
414 (52%)
131 (16%)
144 (18%)		  
64 (15%)
226 (51%)
92 (21%)
60 (14%)		  
168 (18%)
459 (48%)
200 (21%)
120 (13%)		  
82 (15%)
323 (59%)
84 (15%)
60 (11%)
Maintenance immunosuppression,
n (%)
 • Prednisone
 • CNI
 • Mycophenolate
 
801 (100%)
730 (91%)
709 (88%)
 
442 (100%)
397 (90%)
394 (89%)
 
947 (100%)
844 (89%)
857 (90%)
 
549 (100%)
495 (90%)
506 (92%)*

GN, glomerulonephritis; HTN, hypertension; DM, diabetes mellitus; PKD, polycystic kidney disease; HLA, human leukocyte antigen; CNI, calcineurin inhibitor

*

P<0.05 compared to GN